TITLE

Intensive Insulin Therapy in Type 2 Diabetes (T2D) Patients Previously Treated with Glargine Plus Oral Agents: Prandial NPL/Lispro Mixtures vs Glargine/Lispro Basal/Bolus

AUTHOR(S)
Rosenstock, Julio; Ahmann, Andrew J.; Colon, Gildred; Scism-Bacon, Jamie L.; Jiang, Honghua H.; Martin, Sherry
PUB. DATE
June 2007
SOURCE
Diabetes;Jun2007 Supplement 1, Vol. 56, pA51
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
We report the first head-to-head comparison of intensive insulin therapies (intensive mixtures therapy [IMT] vs basal bolus therapy [BBT]) in T2D patients previously treated with glargine (≥30 U/d) + oral agents. Patients with A1C ≥ 7.5 and ≤ 12% were randomized to IMT (lispro mix 50/50; 50% NPL, 50% lispro; n=187) rid with meals or BBT (glargine at bedtime + mealtime lispro; n=187) in a 24-wk, multicenter, open-label, non-inferiority trial using structured insulin titration to achieve fasting/preprandial plasma glucose (PG) <110 mg/dL (<6.1 mM). Patients on IMT not reaching FPG target could switch to lispro mix 75/25 (75% NPL; 25% lispro) at the PM meal. Baseline characteristics were similar (mean): age 55yrs, diabetes duration 11yrs, BMI 34 kg/m² and A1C (IMT 8.8%, BBT 8.9%, P=0.6041). At wk 24, A1C was lower with BBT (6.8 vs 6.9%, P=0.021) and A1C was reduced significantly from baseline for both therapies (P<0.0001). The difference in A1C change from baseline to endpoint (BBT minus IMT) was -0.22% with a 90% CI from -0.38% to -0.06%. Non-inferiority was not demonstrated based on the pre-specified margin of 0.3%. The % of patients on IMT vs BBT achieving target A1C <7.0% was 54% vs 69% (P=0.009) and for target ≤6.5% was 35% vs 50% (P=0.01), but did not differ for target ≤6.0% (14.6% vs 14.3%, P=1.0) or for target <7.5% (81% vs 83%, P=0.76). Treatment with BBT was associated with higher insulin dose (1.38 U/kg vs 1.17 U/kg, P=0.002). Weight gain was similar for both groups (IMT: 3.98 kg vs BBT: 4.55 kg, P=0.22). Rates of overall, nocturnal, severe hypoglycemia, or hypoglycemia confirmed by PG values were also similar. In conclusion, as non-inferiority of IMT to BBT was not demonstrated, findings on A1C reduction, % achieving specific A1C targets, hypoglycemia, insulin dose, and number of injections need to be considered in the individual decision-making process of selecting IMT vs BBT in T2D necessitating intensive insulin therapy.
ACCESSION #
25820513

 

Related Articles

  • No Difference in Cognitive Function, Symptoms or Counter-Regulatory Responses after Induced Hypoglycaemia in Subjects with Type 1 Diabetes. Smeeton, Fiona J.; Shojaee-Moradie, Fariba; Jackson, Nicola; Westergaard, Lisbet; Endahl, Lars; Haahr, Hanne; Umpleby, A. Margot; Russell-Jones, David // Diabetes;Jun2007 Supplement 1, Vol. 56, pA168 

    Insulin detemir (IDet) is a novel long acting insulin analogue. Previous studies have shown a reduced frequency of hypoglycaemia and less weight gain with IDet compared with NPH insulin (NPH). To investigate symptoms, counterregulatory hormone response, cognitive function and metabolism during...

  • More Subjects Treated with Insulin Detemir Achieve HbA[sub 1c] ≤ 7% Without Hypoglycemia and Weight Gain Compared to NPH Insulin. Hermansen, Kjeld; Larsen, Jens; Tamer, Søren C.; Mathieu, Chantal // Diabetes;Jun2007 Supplement 1, Vol. 56, pA130 

    Patients with type 2 diabetes are continuously encouraged to aim for as normal an HbA[sub 1c] level as possible to avoid macro- and micro-vascular complications. With disease progression, the majority of patients require insulin treatment to achieve good control. However, side effects such as...

  • Choosing an Insulin Regimen for Patients With Type 2 Diabetes. Pignone, Michael // Clinical Diabetes;Spring2008, Vol. 26 Issue 2, p63 

    Design. A randomized controlled trial comparing three insulin regimens: biphasic insulin aspart twice daily, prandial insulin aspart three times daily, or basal insulin detemir once daily (with the option of twice daily if needed). Subjects. Participants included 708 patients (64% male) ≥...

  • Avandia May Benefi t Overweight Type 1s. Trecroci, D. // Diabetes Health;Sep2005, Vol. 14 Issue 9, p18 

    Discusses research being done on the efficacy of the type 2 insulin-sensitizing drug Avandia in improving blood glucose control of overweight type 1 diabetics. Reference to a study published in the July 2005 issue of "Diabetes Care" journal; Drug dosage received by the subjects involved in the...

  • Topical Review: A Comprehensive Risk Model for Disordered Eating in Youth With Type 1 Diabetes. Peterson, Claire M.; Fischer, Sarah; Young-Hyman, Deborah // Journal of Pediatric Psychology;May2015, Vol. 40 Issue 4, p385 

    Objectives Provide an updated literature review on prevalence, measurement, and correlates of disordered eating in youth with Type 1 diabetes (T1D), present a novel theoretical risk model (i.e., The Modified Dual Pathway Model) for disordered eating in youth with T1D incorporating psychosocial...

  • Robust Efficacy of Vildagliptin in Drug-Naïve Patients: Pooled Analysis of 5 Monotherapy Studies. Rosenstock, J.; Pi-Sunyer, F. X.; Pratley, R. E.; Couturier, A.; Schweizer, A.; Dejager, S. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA135 

    Vildagliptin is a potent and selective DPP-4 inhibitor that improves glycemic control in patients (pts) with type 2 diabetes (T2DM) by increasing α-and β-cell responsiveness to glucose. In Phase 3 monotherapy trials with vildagliptin, 1682 drug-naïve pts with T2DM were randomized to...

  • Insulin Detemir Improves Glycemic Control and Reduces Hypoglycemia Without Excessive Weight Gain in Children and Adolescents with Type 1 Diabetes: 6-Month Results from Predictiveâ„¢. Robinson, Adam; Hernandez, Francisco; Horn-Rosenberg, Kristine; Luddeke, Hans-Joachim // Diabetes;Jun2007 Supplement 1, Vol. 56, pA699 

    The article discusses the results of a clinical study examining the efficacy of insulin detemir in improving glycemic control and reducing hypoglycemia without excessive weight gain in children and adolescents with type 1 diabetes. The study involved 119 children aged 0-11 years and 244...

  • Combined Therapy With Insulin Plus Oral Agents: Is There Any Advantage? Riddle, Matthew C. // Diabetes Care;Feb2008 Supplement, Vol. 31, pS125 

    The article discusses the benefits of combined therapy with insulin plus oral agents. It states that the combined regimens have been shown to be effective in improving glycemic control in many short-term studies. It says that the combination of metformin with insulin also limits the risk of...

  • The Lowdown.  // Diabetes Forecast;Jun2014, Vol. 67 Issue 6, p20 

    The article reports on the results of a study which determined that too much insulin can cause severe hypoglycemia or lower blood glucose.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics